1. Home
  2. EIG vs GERN Comparison

EIG vs GERN Comparison

Compare EIG & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EIG
  • GERN
  • Stock Information
  • Founded
  • EIG 2000
  • GERN 1990
  • Country
  • EIG United States
  • GERN United States
  • Employees
  • EIG N/A
  • GERN N/A
  • Industry
  • EIG Property-Casualty Insurers
  • GERN Biotechnology: Pharmaceutical Preparations
  • Sector
  • EIG Finance
  • GERN Health Care
  • Exchange
  • EIG Nasdaq
  • GERN Nasdaq
  • Market Cap
  • EIG 986.1M
  • GERN 823.0M
  • IPO Year
  • EIG 2007
  • GERN 1996
  • Fundamental
  • Price
  • EIG $40.29
  • GERN $1.23
  • Analyst Decision
  • EIG Strong Buy
  • GERN Buy
  • Analyst Count
  • EIG 1
  • GERN 7
  • Target Price
  • EIG $58.00
  • GERN $3.17
  • AVG Volume (30 Days)
  • EIG 123.2K
  • GERN 7.6M
  • Earning Date
  • EIG 10-30-2025
  • GERN 11-06-2025
  • Dividend Yield
  • EIG 3.18%
  • GERN N/A
  • EPS Growth
  • EIG N/A
  • GERN N/A
  • EPS
  • EIG 4.10
  • GERN N/A
  • Revenue
  • EIG $889,500,000.00
  • GERN $164,447,000.00
  • Revenue This Year
  • EIG $1.18
  • GERN $172.62
  • Revenue Next Year
  • EIG N/A
  • GERN $56.87
  • P/E Ratio
  • EIG $9.83
  • GERN N/A
  • Revenue Growth
  • EIG 2.32
  • GERN 11877.20
  • 52 Week Low
  • EIG $38.19
  • GERN $1.09
  • 52 Week High
  • EIG $54.44
  • GERN $4.50
  • Technical
  • Relative Strength Index (RSI)
  • EIG 35.91
  • GERN 43.66
  • Support Level
  • EIG $40.20
  • GERN $1.19
  • Resistance Level
  • EIG $42.31
  • GERN $1.31
  • Average True Range (ATR)
  • EIG 0.65
  • GERN 0.06
  • MACD
  • EIG -0.11
  • GERN -0.00
  • Stochastic Oscillator
  • EIG 9.36
  • GERN 15.38

About EIG Employers Holdings Inc

Employers Holdings Inc is a provider of workers' compensation insurance and services focused on small and mid-sized businesses engaged in low-to-medium hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations, through its wholly owned subsidiaries.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: